30 Oct 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Boston Scientific has received China Food and Drug Administration (CFDA) approval for Alair Bronchial Thermoplasty System, an innovative medical device designed to treat severe asthma.
The Alair system, which is expected to be available in China later this year, provides therapy for patients with severe asthma which is not well controlled with inhaled corticosteroids and long-acting beta-agonists.
Bronchial Thermoplasty (BT) is a bronchoscopic procedure typically performed under moderate sedation on an outpatient basis. Delivered by the Alair System, BT uses mild heat to reduce the excessive smooth muscle tissue in the airways. This reduces airway constriction during an asthma attack, making attacks less frequent and less severe.
"We are delighted to see that the Boston Scientific Alair Bronchial Thermoplasty System has been officially certified by the China Food and Drug Administration," said Mr Warren Wang, vice president and managing director-China, Boston Scientific.
"Unlike conventional treatments, Bronchial Thermoplasty offers a viable new option for patients suffering from severe asthma thanks to its breakthrough technology and mechanism of action. We believe this device can markedly improve the quality of life of asthma patients here in China," Mr Wang added.